Anti_Mouse, mab OSCAR Source Rat
- Known as:
- Anti_Mouse, mab OSCAR Source Rat
- Catalog number:
- 103-M447
- Product Quantity:
- 100 µg
- Category:
- -
- Supplier:
- Reliatech
- Gene target:
- Anti_Mouse mab OSCAR Source Rat
Related genes to: Anti_Mouse, mab OSCAR Source Rat
- Gene:
- OSCAR NIH gene
- Name:
- osteoclast associated Ig-like receptor
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 19q13.42
- Locus Type:
- gene with protein product
- Date approved:
- 2007-06-21
- Date modifiied:
- 2019-02-21
Related products to: Anti_Mouse, mab OSCAR Source Rat
Related articles to: Anti_Mouse, mab OSCAR Source Rat
- Programmed death ligand-1 (PD-L1) expression is a key biomarker for identifying non-small cell lung cancer (NSCLC) patients eligible for immunotherapy, but its immunohistochemistry assessment is subject to high interobserver variability. This study aimed to develop and validate an automated system based on artificial intelligence (AI) to detect and classify PD-L1-positive cells in digital lung biopsies from Latin American patients with NSCLC. A total of 141 biopsies were digitized, and deep learning models were trained for tissue segmentation and analysis. YOLOv8 was used for cell detection and ResNet50 for classification into four categories (tumor or non-tumor cells, PD-L1 positive or negative). The tumor proportion score (TPS) was calculated using these classifications. The YOLOv8 model achieved 76% precision and a mAP@0.5 of 63.7% in cell detection, whereas ResNet50 reached 85.2% sensitivity in identifying PD-L1-positive tumor cells. The TPS estimated by the system demonstrated 97% concordance with manual evaluation by an expert pathologist. In addition, spatial PD-L1 maps revealed intratumoral heterogeneity, supporting its relevance for immunotherapy decisions. These findings show that automated PD-L1 quantification using AI is feasible and accurate, improves diagnostic reproducibility, and supports personalized treatment decisions, especially in resource-limited settings. - Source: PubMed
Publication date: 2026/05/31
Rodríguez Jorge LuisRodríguez EduardGil RichardSánchez NataliaGómez-Lopera NataliaRojas LeonardoZuluaga JairoViola LuciaMartínez StellaCarvajal CarlosGonzalez AlejandroZuluaga ClarenaRodríguez FernandoÁvila VanezaWagner-Gutiérrez NicolleArrieta OscarCardona Andres F - Antiangiogenic therapies have been extensively investigated in advanced/metastatic gastric cancers, but also in neoadjuvant settings. The anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) monoclonal antibody ramucirumab was the first antiangiogenic agent approved for HER2-negative metastatic gastric adenocarcinomas and remains a standard second-line treatment either alone or in combination with paclitaxel. Other VEGFR-targeting agents, such as the tyrosine kinase inhibitors (TKI) regorafenib and apatinib, have failed to demonstrate any survival benefit in the first-line settings, while providing modest improvements in pretreated patients, even when combined with Immune Checkpoint Inhibitors (ICI). Despite showing no significant benefit in Caucasian patients, apatinib has been approved in China for pretreated patients with advanced/metastatic gastric cancer. Dose-limiting toxicities, and the lack of robust predictive biomarkers for patients' stratification may both contribute to the limited efficacy of these multi-target tyrosine kinase inhibitors in gastric cancers. Several ongoing clinical trials mostly conducted in China suggest that new generation of antiangiogenic agents, particularly bispecific antibodies targeting both VEGF and Programmed Cell Death 1 (PD-1) or its ligand PD-L1, may offer greater efficacy with reduced toxicity. However, these promising preliminary data await mature overall survival results as well as clinical validation in the global population. Developing more effective drugs is closely linked to identifying reliable predictive biomarkers, which are crucial for guiding patients' selection, monitoring treatment response and optimizing therapeutic combinations and sequencing. Although several biomarker candidates have been explored, reliable predictors are still awaited. This review summarizes current evidence and explores the future of antiangiogenic agents in gastric cancers. - Source: PubMed
Publication date: 2026/06/24
Raimbourg JudithAbdelghani Meher BenBoige ValerieBotsen DamienCarnot AurélienCoutzac CléliaDelaye MatthieuDe Sousa Carvalho NicolasDos Santos MélanieEdeline JulienGhiringhelli FrançoisLambert AurélienLe Sourd SamuelPalmieri Lola-JadePernot SimonSamalin EmmanuelleSmolenschi CristinaVivier-Chicoteau JustineMarion Sébastiende la Fouchardière Christelle - Circulating nucleosomes (DNA wound around histone proteins) are emerging cancer biomarkers. We investigated their association with clinical outcomes in advanced ovarian cancer. - Source: PubMed
Publication date: 2026/07/01
Corbaux PaulineColomban OlivierLescuyer GaelleRay-Coquard IsabelleDe Rauglaudre GaëtanJoly FlorenceAbdeddaim CyrilCombe PierreBlonz CyriacBataillon GuillaumeMeunier JérômeAlexandre JérômeBerton DominiqueKaminsky Marie-ChristineBello Roufai DianaLeary AlexandraVenat LaurenceDohollou NadineLouvet ChristopheLebreton CoriolanAbadie-Lacourtoisie SophieLotz Jean-PierreFavier LaureFabbro MichelBonichon-Lamichhane NathalieKurtz Jean-EmmanuelFollana PhilippePujade-Lauraine EricPayen LeaYou Benoit - The main objective of this study was to develop economic selection indices (IM€T) for different dairy production systems (conventional, cheese-oriented, grazing, and organic) by incorporating production, functional, and sustainability-related traits, including enteric methane and feed intake. The potential inclusion of microbiome-derived information was also evaluated in conventional and organic production systems. Relative to a baseline scenario without emphasis on sustainability, the new indices assigned a negative economic weight (1%) to methane emissions. Organic systems, with a larger economic value applied on methane, resulted in a relative weight of 11% for methane production. Feed intake also received a negative economic weight, ranging from 13 to 15% across production systems. The inclusion of sustainability-related traits primarily reduced the economic emphasis on milk and protein yield, with the largest trade-offs observed in organic systems. Longevity also showed a slight reduction in relative economic weight when dry matter intake and methane production were included in the breeding goal. Grazing and organic systems applied a larger weight on longevity, in comparison to IM€T_milk. Predicted genetic responses indicated the greatest expected improvements in reduced methane emissions and enhanced feed efficiency, although these gains were accompanied by lower rates of genetic progress for production traits and longevity. Substituting methane emission and feed intake traits with microbiome-derived information resulted in larger predicted reductions in methane emissions and feed costs, while also improving genetic gain for fat yield. The expected increase in overall genetic gain for profit ranged from 10 to 30% when microbiome information was incorporated. The inclusion of methane emissions and feed intake in selection indices is expected to contribute to shaping the phenotype of future dairy cattle by 2050, emphasizing environmental efficiency alongside traditional productivity traits. Rumen microbiome information showed strong genetic correlations with methane emissions (|r| > 0.74) and feed efficiency (|r| > 0.64), suggesting that it may represent a novel trait for inclusion in dairy breeding programs, although further research is required to validate its utility. - Source: PubMed
Publication date: 2026/06/30
González-Recio OMohedano ALópez-Paredes JTeran EMartínez-Álvaro MJiménez-Montero J A - Patients with metastatic hormone-sensitive prostate cancer (mHSPC) require long-term treatment to delay progression and improve survival, while minimizing adverse events or negative impact on symptoms (e.g. pain) and health-related quality of life (HRQoL). In ARASENS (NCT02799602), darolutamide plus androgen deprivation therapy (ADT) and docetaxel significantly improved overall survival (primary endpoint) versus placebo plus ADT and docetaxel. We report clinically relevant endpoints and HRQoL in ARASENS. - Source: PubMed
Publication date: 2026/06/12
Fizazi KarimSmith Matthew RHussain MahaSaad FredSternberg Cora NDavid Crawford EAragon-Ching Jeanny BSchostak MartinTutrone RonaldMorgans Alicia KSentana-Lledo DanielJoensuu HeikkiMohamed Ateesha FLittleton NatashaSrinivasan ShankarButtkewitz YvonneLi RuiKuss IrisTombal Bertrand